## PROACTIVE VERSUS RETROACTIVE MODELS IN MEDICATION **RECONCILIATION – ARE THERE BENEFITS?**



. . . . .

• •

• •

• •

• •

• •

| <b>A. LEAL, S. MARQUES, T.</b>  | <b>CUNHA, P. BARBEITA, P. ROCHA</b><br>cal de Saúde de Santo António, Porto, Portugal |   | european association<br>of hospital pharmacists |
|---|---|---|---|
| BACKGROUND AND IMPORTANCE   |   | P | <b>Poster n. 4CPS-241</b>                       |
| Medication Reconciliation (MR) at admission has been rising in Portugal; however, its implementation predominantly focuses on the Retroactive model, with limited or no experience applying the Proactive model.         Comparative data between these two approaches remain scarce in the Literature—fewer than five scientific articles have |   |   |   |
| been published—underscoring the <b>pioneering nature of thi</b>   | is study.   |   |   |

. . . . . . . . . . . . . . . . .



. . . . . .

. . . .

. . . .

. . . .

. . . .

. . . .

. . . .

. . . .

. . . .

. . . .

. . . .

•••

• •

. . .

. . .

• • •

. . .

. . .

• • •

• • •

• • •

• • •

## **AIMS AND OBJECTIVES**

Characterize and compare Retroactive and Proactive MR particularly regarding the number processes, ot **Unintentional Discrepancies (UD)** that can lead to Drug Related Problems (DRPs).

To explore each model in the average length of hospital stay.

To investigate the connection between the **admission waiting list,** prior and following, to implementation of MR.

## MATERIALS AND **METHODS**

Prospective study conducted for twelve months in a Vascular Surgery unit (October 2023 to September 2024). **Inclusion criteria:** presence of comorbidities, age  $\geq 55$ years, prior chronic therapy with  $\geq$  5 drugs. Data collection and analysis using Microsoft Excel.

\*Model classification depending on prescription and medication history availability.





2024.

| $\cdot\cdot\cdot {\sf L} \_$   |   |
|--|---|
| <b>CONCLUSION AND RELEVANCE</b>  | • • • • • • • • • • • • • • • • • • •   |
| <ul> <li>Proactive MR model demonstrated remarkable benefits over of leading t</li> <li>Shorter hospital stays and greater patient recovery were obse</li> <li>Overall, MR and PI may have contributed to reduced treated strengthen these findings.</li> </ul>  | the Retroactive model in <b>early prevention of UDs</b> capable<br>o DRPs.<br>rved, suggesting better bed availability.<br><b>nent waiting lists</b> , though further monitoring is needed to |
| <ul> <li><u>References:</u></li> <li>Levesque T, Abdelaziz H, Smith A, Cormier N, Bernard M, Laplante M, et al. Medication Reconciliation at Hospital Admission: Propert. 2021;37:545–51.</li> <li>Gomes T, Greaves S, van den Brink M, Bjerre LM, Brosen K, Gilron I, et al. Pregabalin and the Risk for Opioid-Related Death: A 2018;169(10):732–4.</li> </ul> | Deactive Versus Retroactive Models. Drugs Ther<br>Nested Case–Control Study. Ann Intern Med.  |